TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Enanta Pharmaceuticals ( (ENTA) ) has shared an update.
On September 29, 2025, Enanta Pharmaceuticals announced positive topline data from its Phase 2b study of zelicapavir for treating respiratory syncytial virus (RSV) in high-risk adults. The study showed that zelicapavir, a novel N-protein inhibitor, significantly improved the time to complete resolution of RSV symptoms and demonstrated a favorable safety profile. The results suggest potential for zelicapavir as a first-in-class RSV treatment, reducing symptom duration and hospitalization rates in high-risk adults.
The most recent analyst rating on (ENTA) stock is a Sell with a $7.00 price target. To see the full list of analyst forecasts on Enanta Pharmaceuticals stock, see the ENTA Stock Forecast page.
Spark’s Take on ENTA Stock
According to Spark, TipRanks’ AI Analyst, ENTA is a Underperform.
Enanta Pharmaceuticals’ overall stock score is primarily impacted by its poor financial performance, characterized by significant losses, high leverage, and cash flow issues. Technical analysis indicates bearish momentum, while valuation metrics highlight ongoing profitability challenges. The absence of earnings call data and corporate events further limits positive influences on the score.
To see Spark’s full report on ENTA stock, click here.
More about Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing small molecule drugs for viral infections and immunological diseases.
Average Trading Volume: 208,509
Technical Sentiment Signal: Sell
Current Market Cap: $168.9M
Find detailed analytics on ENTA stock on TipRanks’ Stock Analysis page.